{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of patients with progression.","groupId":"OG000","lowerLimit":"3.0","upperLimit":"NA","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"On-study date until disease progression or death. Progression is \\>= 20% increase in the sum of diameters of target lesions or non-target lesions, or appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.\n\nAvelumab: Avelumab through a vein once every 2 weeks","id":"OG000","title":"Avelumab Monotherapy"}],"paramType":"MEDIAN","populationDescription":"all participants","reportingStatus":"POSTED","timeFrame":"On-study date to lesser of date of progression or date of death from any cause measured up to 3 years after treatment","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}